Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation: An 8-year longitudinal comparison with mitral valve replacement and inherited thrombophilia

Thrombosis and Haemostasis

Volumn 93, Issue 4, 2005, Pages 694-699

  Ames, Paul R J ^a,e   Ciampa, Antonio ^b   Margaglione, Maurizio ^c   Scenna, Giovanna ^d   Iannaccone, Luigi ^d   Brancaccio, Vincenzo ^d  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^b S G MOSCATI HOSPITAL   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

^d CARDARELLI HOSPITAL   (Italy)

^e LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Anticardiolipin; Antiphospholipid; Lupus anticoagulant; Thrombosis; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; CARDIOLIPIN ANTIBODY; ENOXAPARIN; IMMUNOGLOBULIN G; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); WARFARIN;

ADULT; AGED; ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BIOASSAY; BLEEDING; BLOOD VESSEL OCCLUSION; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; ECCHYMOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPISTAXIS; FATALITY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GINGIVA BLEEDING; HEART INFARCTION; HEMATURIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; ITALY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REPLACEMENT; MUSCLE HEMATOMA; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGRESSION ANALYSIS; SEX DIFFERENCE; STROKE; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS; VAGINA BLEEDING;

ADULT; AGED; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; DOSE-RESPONSE RELATIONSHIP, DRUG; FAMILY HEALTH; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HEMORRHAGE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MITRAL VALVE; PREDICTIVE VALUE OF TESTS; RECURRENCE; THROMBOPHILIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 16844366230     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-11-0723     Document Type: Article

References (17)

1. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303-8.
2. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid syndrome. N Engl J Med 1995: 332: 993-7.
3. Ruiz-Irastorza Guillermo, Khamashta MA, Hunt BJ, et al. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome. Analysis of a series of 66 patients treated with oral anticoagulation to a target international normalised ratio of 3.5. Arch Intern Med 2002; 162: 1164-9.
4. Schulman S, Svenungsson E, Grandqvist S and the Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence in thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998; 104: 332-8.
5. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-91.
6. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8.
7. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11.
8. Greaves M, Cohen H, MacHin SJ, et al. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109: 704-15.
9. Brancaccio V, Ames PRJ, Glynn J, et al. A rapid screen for lupus anticoagulant (LA) by comparing a sensitive and insensitive aPTT reagent provides also good discrimination from oral anticoagulants, congenital factor deficiency and heparin. Blood Coagul Fibrinolysis 1997; 8: 155-60.
10. Ames PRJ, Pyke S, Iannaccone L, et al. Antiphospholipid antibodies, haemostatic variables and thrombosis - A survey of 144 patients. Thromb Haemost 1995; 73: 768-73.
11. Meroni PL, Moia M, Derksen RHWM, et al. Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis. Lupus 2003; 12: 504-7.
12. Alarcon-Segovia D, Boffa MC, Branch W, et al. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 2003; 12: 499-503.
13. Ames PRJ, Iannaccone L, Tommasino C, et al. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies. A crucial role for acquired free protein S deficiency. Thromb Haemost 1996; 76: 190-4.
14. Cervera R, Piette JC, Font J, et al. Euro Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-27.
15. Orlando E, Cortelazzo S, Marchetti M, et al. Prolonged bleeding time in patients with lupus anticoagulant. Thromb Haemost 1992; 68: 495-9.
16. Erkan D, Leibowitz E, Berman J, et al. Perioperative management of antiphospholipid syndrome: hospital for special surgery experience, review of the literature and recommendations. J Rheumatol 2002; 29: 843-9.
17. Madan R, Khoursheed M, Kukla R, et al. The anaesthetist and the antiphospholipid syndrome. Anaesthesia 1997; 52: 72-6.